Modality
siRNA
MOA
PI3Ki
Target
PLK4
Pathway
JAK/STAT
IPFASMelanoma
Development Pipeline
Preclinical
Apr 2025
→ Jun 2025
PreclinicalCurrent
NCT06585696
669 pts·IPF
2025-04→2025-06·Terminated
669 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-06-269mo agoInterim· IPF
Trial Timeline
Q2
Preclinical
Termina…
Catalysts
Interim
2025-06-26 · 9mo ago
IPF
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06585696 | Preclinical | IPF | Terminated | 669 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| REG-3155 | Regeneron | Phase 1/2 | MDM2 | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| SRP-3270 | Sarepta | Phase 1/2 | SGLT2 | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 | |
| Pexaosocimab | United Therapeutics | NDA/BLA | PLK4 |